Stryker (NYSE:SYK) Shares Unloaded Rep. Thomas H. Kean, Jr.

Key Points

• Rep. Thomas H. Kean Jr. sold $1,001–$15,000 of Stryker shares on July 22, according to a disclosure filed August 18. He also reported several other stock sales and purchases, including sales of Alphabet and purchases of ESAB.
• Stryker reported quarterly adjusted earnings of $3.69 per share, beating estimates of $3.49, while revenue rose 9.4% year over year to $6.59 billion. The company maintained fiscal 2026 EPS guidance of $14.95–$15.10.
• Stryker declared a quarterly dividend of $0.88 per share, equivalent to an annualized $3.52 payout and a 1.0% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $386.28.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Stryker Corporation NYSE: SYK. In a filing disclosed on August 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Stryker stock on July 22nd. The trade occurred in the Representative's "STATE STREET BANK & TRUST CO." account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 7/22/2026.
• Sold $1,001 - $15,000 in shares of Analog Devices NASDAQ: ADI on 6/30/2026.
• Sold $1,001 - $15,000 in shares of S&P Global NYSE: SPGI on 6/29/2026.
• Sold $1,001 - $15,000 in shares of Markel Group NYSE: MKL on 6/29/2026.
• Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 6/29/2026.
• Purchased $1,001 - $15,000 in shares of ESAB NYSE: ESAB on 6/24/2026.
• Sold $15,001 - $50,000 in shares of Alphabet NASDAQ: GOOGL on 6/24/2026.
• Purchased $1,001 - $15,000 in shares of ESAB NYSE: ESAB on 6/22/2026.
• Sold $1,001 - $15,000 in shares of Gildan Activewear NYSE: GIL on 6/17/2026.
• Purchased $1,001 - $15,000 in shares of Wheaton Precious Metals NYSE: WPM on 6/4/2026.

Stryker Price Performance

SYK opened at $340.20 on Thursday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The company's 50 day simple moving average is $326.19 and its 200 day simple moving average is $332.95. The stock has a market capitalization of $130.49 billion, a PE ratio of 35.25, a P/E/G ratio of 2.11 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, sell-side analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. Stryker's dividend payout ratio is currently 36.48%.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SYK. Needham & Company LLC dropped their price objective on Stryker from $454.00 to $418.00 and set a "buy" rating for the company in a report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a report on Friday, May 1st. Royal Bank Of Canada lowered their price target on Stryker from $435.00 to $420.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. BMO Capital Markets initiated coverage on Stryker in a report on Wednesday, July 8th. They issued an "outperform" rating and a $369.00 price objective on the stock. Finally, Robert W. Baird set a $385.00 price objective on Stryker in a research note on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and an average target price of $386.28.

Insider Transactions at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This trade represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 315,370 shares of company stock worth $98,463,501. 4.60% of the stock is currently owned by company insiders.

Institutional Trading of Stryker

Several institutional investors have recently added to or reduced their stakes in SYK. Gables Capital Management Inc. acquired a new position in shares of Stryker in the 2nd quarter valued at about $25,000. Kilter Group LLC acquired a new stake in Stryker during the second quarter worth about $25,000. Godfrey Financial Associates Inc. bought a new position in Stryker in the fourth quarter worth about $26,000. Sankala Group LLC acquired a new position in Stryker in the fourth quarter valued at approximately $26,000. Finally, Compass Financial Management LLC acquired a new position in Stryker in the second quarter valued at approximately $27,000. Institutional investors own 77.09% of the company's stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source